JP2003501460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003501460A5 JP2003501460A5 JP2001502830A JP2001502830A JP2003501460A5 JP 2003501460 A5 JP2003501460 A5 JP 2003501460A5 JP 2001502830 A JP2001502830 A JP 2001502830A JP 2001502830 A JP2001502830 A JP 2001502830A JP 2003501460 A5 JP2003501460 A5 JP 2003501460A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- tumor growth
- medicament
- medicament according
- immunotherapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 20
- 230000004614 tumor growth Effects 0.000 description 17
- 239000002955 immunomodulating agent Substances 0.000 description 14
- 239000012035 limiting reagent Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000003902 lesion Effects 0.000 description 6
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 5
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 description 5
- NCHSTTAWIMAJHU-UHFFFAOYSA-N (4-oxo-2-phenylchromen-3-yl) acetate Chemical compound O1C2=CC=CC=C2C(=O)C(OC(=O)C)=C1C1=CC=CC=C1 NCHSTTAWIMAJHU-UHFFFAOYSA-N 0.000 description 4
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 4
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 1
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229950008737 vadimezan Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ336259 | 1999-06-14 | ||
| NZ33625999 | 1999-06-14 | ||
| PCT/NZ2000/000098 WO2000076497A1 (en) | 1999-06-14 | 2000-06-14 | Cancer therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003501460A JP2003501460A (ja) | 2003-01-14 |
| JP2003501460A5 true JP2003501460A5 (enExample) | 2007-08-02 |
| JP4638098B2 JP4638098B2 (ja) | 2011-02-23 |
Family
ID=19927331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001502830A Expired - Fee Related JP4638098B2 (ja) | 1999-06-14 | 2000-06-14 | 癌治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040086498A9 (enExample) |
| EP (1) | EP1189611B1 (enExample) |
| JP (1) | JP4638098B2 (enExample) |
| AT (1) | ATE324888T1 (enExample) |
| AU (1) | AU5717400A (enExample) |
| DE (1) | DE60027719T2 (enExample) |
| ES (1) | ES2265948T3 (enExample) |
| WO (1) | WO2000076497A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001247459A (ja) | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| US20070021392A1 (en) * | 2000-03-31 | 2007-01-25 | Davis Peter D | Divided dose therapies with vascular damaging activity |
| PT1272200E (pt) * | 2000-03-31 | 2005-09-30 | Angiogene Pharm Ltd | Terapeuticas em doses fraccionadas com actividade de degradacao vascular |
| AU2001282717A1 (en) * | 2000-07-28 | 2002-02-13 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| FR2832154B1 (fr) | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
| GB2384428A (en) * | 2002-01-29 | 2003-07-30 | Thromb X Nv | Inhibitors of HIF |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| HUE037352T2 (hu) | 2002-04-05 | 2018-08-28 | Roche Innovation Ct Copenhagen As | A HIF-1alfa expresszálódását módosító oligomer vegyületek |
| NZ520321A (en) * | 2002-07-19 | 2005-03-24 | Auckland Uniservices Ltd | Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal |
| US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
| EP1560931B1 (en) | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US7619081B2 (en) | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
| US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
| US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
| US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
| US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
| US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
| US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| JP4546454B2 (ja) * | 2003-01-28 | 2010-09-15 | レクサーン・コーポレイション | Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド |
| ES2333794T3 (es) * | 2003-01-31 | 2010-03-01 | Rexahn Pharmaceuticals, Inc. | Oligonucleotidos que inhiben la expresion de hif-1. |
| FR2835838B1 (fr) * | 2003-02-06 | 2007-11-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription |
| US20050070474A1 (en) * | 2003-04-28 | 2005-03-31 | Krissansen Geoffrey Wayne | Methods of treatment and compositions therefor |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
| WO2005032486A2 (en) * | 2003-10-02 | 2005-04-14 | Duke University | A NOVEL SIRNA-BASED APPROACH TO TARGET THE HIF-α FACTOR FOR GENE THERAPY |
| US7605250B2 (en) | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
| US7618947B2 (en) * | 2004-08-25 | 2009-11-17 | Isis Pharmaceuticals, Inc. | Modulation of HIF-1 beta expression |
| US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
| NZ555644A (en) | 2004-11-09 | 2009-04-30 | Santaris Pharma As | Potent LNA oligonucleotides for the inhibition of HIF-1A expression |
| US20100297112A1 (en) * | 2005-08-26 | 2010-11-25 | Antisoma Research Limited | Combinations comprising dmxaa for the treatment of cancer |
| US10307490B2 (en) | 2012-05-23 | 2019-06-04 | The Ohio State University | Lipid nanoparticle compositions for antisense oligonucleotides delivery |
| SG11201407875UA (en) | 2012-06-08 | 2014-12-30 | Aduro Biotech | Compostions and methods for cancer immunotherapy |
| CA2908154C (en) | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| JP2016518140A (ja) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｉ型インターフェロンの環状ジヌクレオチド誘導法 |
| DK2996473T3 (da) | 2013-05-18 | 2019-11-04 | Aduro Biotech Inc | Sammensætninger og fremgangsmåder til aktivering af "stimulator af interferon-gen"-afhængig signalering |
| EP3027227A4 (en) | 2013-07-31 | 2018-05-23 | Memorial Sloan Kettering Cancer Center | Sting crystals and modulators |
| JP2016538344A (ja) * | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| US11058758B2 (en) | 2014-11-20 | 2021-07-13 | National Institutes Of Biomedical Innovation, Health And Nutrition | TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3655470A (en) * | 1969-03-29 | 1972-04-11 | Toa Gosei Chem Ind | Process for the production of a foamed thermoplastic resin sheet |
| FR2516922A1 (fr) * | 1981-11-25 | 1983-05-27 | Lipha | Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant |
| CA1264738A (en) * | 1984-12-04 | 1990-01-23 | Eli Lilly And Company | Treatment of tumors in mammals |
| US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| EP0278176B1 (en) * | 1986-12-23 | 1994-03-09 | Warner-Lambert Company | Compounds having antitumour and antibacterial properties |
| US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| JPH01193227A (ja) * | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | 癌免疫療法補助剤 |
| US5075287A (en) * | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
| JPH03116857A (ja) * | 1989-09-29 | 1991-05-17 | Mitsui Petrochem Ind Ltd | 発光または受光装置 |
| US5250296A (en) * | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
| US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
| JPH0940690A (ja) * | 1995-05-23 | 1997-02-10 | Yutaka Sashita | ステロイド配糖体及びこれを有効成分とする医薬 |
| US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| US5977077A (en) * | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
| US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
| US5817684A (en) * | 1996-12-13 | 1998-10-06 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke |
| US5910505A (en) * | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
| US5998454A (en) * | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
| US5914340A (en) * | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
| DE19721211A1 (de) * | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| DE60018225T2 (de) * | 1999-03-01 | 2005-12-29 | Pfizer Products Inc., Groton | Oxamsäuren mit einer Cyanogruppe als Liganden für den Thyroidrezeptor |
| US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
| WO2001060365A1 (en) * | 2000-02-17 | 2001-08-23 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
| JP2001247459A (ja) * | 2000-03-03 | 2001-09-11 | Oakland Uniservices Ltd | 癌の組み合わせ療法 |
| AU2001282717A1 (en) * | 2000-07-28 | 2002-02-13 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
| GB0121285D0 (en) * | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2386836B (en) * | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
-
2000
- 2000-06-14 WO PCT/NZ2000/000098 patent/WO2000076497A1/en not_active Ceased
- 2000-06-14 AT AT00942571T patent/ATE324888T1/de not_active IP Right Cessation
- 2000-06-14 EP EP00942571A patent/EP1189611B1/en not_active Expired - Lifetime
- 2000-06-14 ES ES00942571T patent/ES2265948T3/es not_active Expired - Lifetime
- 2000-06-14 AU AU57174/00A patent/AU5717400A/en not_active Abandoned
- 2000-06-14 JP JP2001502830A patent/JP4638098B2/ja not_active Expired - Fee Related
- 2000-06-14 DE DE60027719T patent/DE60027719T2/de not_active Expired - Lifetime
-
2001
- 2001-12-11 US US10/014,887 patent/US20040086498A9/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003501460A5 (enExample) | ||
| Yeh et al. | Hypoxic preconditioning reinforces HIF-alpha-dependent HSP70 signaling to reduce ischemic renal failure-induced renal tubular apoptosis and autophagy | |
| TWI308492B (enExample) | ||
| CZ2003553A3 (cs) | Farmaceutický prostředek | |
| JPH10503522A (ja) | 化学療法剤とともに使用するための防御性プロスタグランジン | |
| US20050112061A1 (en) | Use of a VEGF antagonist in combination with radiation therapy | |
| Nagata et al. | Pigmented plaques associated with papillomavirus infection in dogs: is this epidermodysplasia verruciformis? | |
| US20050196340A1 (en) | Use of a VEGF antagonist in combination with radiation therapy | |
| Pantoja et al. | Gigantic cystosarcoma phyllodes in a man with gynecomastia | |
| JP2005501068A (ja) | 特に眼科分野における適用のための外傷および損傷の治癒および／または修復のための治療に適したアミノ酸組成物 | |
| Cohen et al. | Influence of trauma on the unusual distribution of metastases from carcinoma of the larynx | |
| JP2005505540A5 (enExample) | ||
| WO2025113347A1 (zh) | 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途 | |
| WO2024198712A1 (zh) | 一种应用于肝癌治疗的寡核苷酸药物制剂及其制备方法和应用 | |
| US5869446A (en) | Preparation of lactoferrin (or serotransferrin or ovotransferrin) and desferrioxamine methanesulfonate (or other low molecular weight metal ion chelators) for the therapy of viral infections | |
| JP2020522568A (ja) | テセタキセル及びカペシタビンの投与スケジュール | |
| McIver et al. | Choroid plexus papilloma and meningioma: coincidental posterior fossa tumors: case report and review of the literature | |
| JP2020525448A (ja) | ソニックヘッジホッグシグナル伝達経路を介する脊椎円板変性を治療する組成物、使用及び方法 | |
| JP2004175692A (ja) | 抗腫瘍剤 | |
| CN118743670B (zh) | 一种用于锰免疗法的超分子水凝胶及其制备方法和应用 | |
| JP2014231518A (ja) | 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用 | |
| JPH10175852A5 (enExample) | ||
| Mattis et al. | Dapagliflozin-induced sweet syndrome | |
| Koff | Chronic hepatitis C: early intervention | |
| US7091205B2 (en) | Use of tetramethylpyrazine in the treatment of brain tumor |